AXON THERAPY mPNS® FOR HEALTHCARE PROVIDERS
The Breakthrough Platform
for Treating Chronic Pain
The Breakthrough Platform for Treating Chronic Pain
The Next Evolution of Neuromodulation is in Your Hands
TREAT MORE PATIENTS WITH AXON THERAPY mPNS
What If You Had a Non-Invasive
Way to Treat Pain That’s As
Effective As Invasive Options?
What If You Had a Non-Invasive Way to Treat Pain That’s As Effective As Invasive Options?
It’s a New Day for Neuromodulation
Axon Therapy mPNS represents a breakthrough in treating chronic neuropathic pain for patients suffering from post-traumatic surgical pain, post amputation pain, and phantom limb pain.
As new clinical trials take place, the Axon Therapy electroceutical platform is also being tested for a multitude of indications, including urinary incontinence and painful diabetic neuropathy (PDN).
Revolutionizing Chronic Neuropathic Pain
Using painless magnetic pulses, Axon Therapy mPNS provides patients with equivalent or greater clinical benefits of neuromodulation than would be possible with invasive and painful methods such as PNS, implants, or surgery.
In clinical trials, ⅔ of patients report an 87% avg. reduction in pain over the treatment period.1
1VA Augusta Clinical Equipment Evaluation (CEC)
Improve Your Patient Management
With its simple handheld technology, Axon Therapy mPNS enables physicians to provide neuromodulation treatments to patients in a fraction of the time and cost. Treatments can be easily administered in a clinic environment, making it faster and more convenient than PNS.
100% Painless and Non-Invasive Neuromodulation
With no needles, no implants, and no risk of infection, healthcare providers can harness Axon Therapy mPNS to test more nerve areas quicker, getting to the root cause of neuropathic pain faster and more effectively than conventional PNS. Physicians simply position the device near or above the skin to administer painless magnetic pulses that recondition the central nervous system by eliminating noxious pain signals to the brain.
A Stepwise Approach to Chronic Neuropathic Pain
Most often, chronic neuropathic pain is treated through medications or intervention, but Axon Therapy mPNS represents a new approach for physicians.
With its innovative mechanism of action, Axon Therapy mPNS can be administered in clinic as a spot treatment, with respondent patients reporting immediate pain relief after just one treatment.
COST SAVINGS AT THE VA
Why mPNS (magnetic Peripheral Nerve Stimulation - Axon Therapy) makes Health Economic sense for VA Facilities
Proven Impact at Charlie Norwood VAMC: Axon Therapy’s trial at the Charlie Norwood VAMC in Augusta, Georgia, set new benchmarks. With two-thirds of patients experiencing a significant 65% pain reduction and a 51% drop in opioid use, the evidence is compelling. One-year follow-ups confirm the effects are not only sustained with monthly treatments but also durable. Reinforced by two Randomized Control Trials (RCTs)—the SEAT study and the study on Axon Therapy for Painful Diabetic Peripheral Neuropathy—results were even more impressive, leading to the latest FDA clearance for PDN treatment. Axon Therapy’s inclusion in the ASPN Algorithm Guidelines for the first time underscores its effectiveness and innovation.
Cost-Effective Solution: Economic analyses favor Axon Therapy over other neuromodulation methods due to its lower costs and superior Quality-Adjusted Life Year (QALY) metrics.
mPNS $/QALY Compared to Current $/QALY Threshold
No Data Found
VA Health Economics—A Perfect Fit
With Community Care costs reverting to Individual Health Centers, the priority shifts towards more cost-effective, efficient, and side-effect-free treatments.
Axon stands out: noninvasive, no implant risks, no complications, and consistently effective for those who’ve exhausted other options, requiring just once-a-month sessions.
It promises to reduce the need for external Peripheral Nerve Stimulator implants and spinal cord stimulators—among the priciest pain management treatments. Now accessible through the E-CAT system for VA and DOD facilities, Axon Therapy represents a strategic move to cut Community Care pain management costs while boosting patient outcomes and satisfaction.
No Data Found
Citations:
- Bedder M, Parker L. “Magnetic Peripheral Nerve Stimulation (mPNS) for Chronic Pain.” J Pain Res. 2023 Jul 12;16:2365-2373.
- In press: Journal of Pain Research.
HOW IT WORKS
Mechanism of Action: Superior Magnetic
Strength & Exceptional Recruitment
Mechanism of Action: Superior Magnetic Strength & Exceptional Recruitment
Neuralace Medical is the first to configure a high intensity magnetic field into
a small physical footprint for peripheral nerve stimulation.
No other medical technology platform combines the same low frequency (0-5 Hz),
unique pulse width, and proprietary treatment algorithm into a wheelable, plug-in 2’x2’ form factor.
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
Axon Therapy mPNS is the only device of its kind that is FDA-cleared for post surgical and post traumatic neuropathic pain.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
The mPNS pulse is delivered at a distance from the nerve, and is not attenuated by the skin or tissue, thereby delivering maximum effect.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
Smaller diameter fibers (A-delta & C) are not concomitantly activated during treatments.
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
The handheld mPNS coil is optimized to deliver specific pulses of a proprietary frequency and wavelength that only activate large diameter nerve fibers (A-alpha and A-beta).
SCS
DRG
Conventional PNS
mPNS
EFFECTIVELY RESTORING NERVE FUNCTIONALITY
Achieve Maximal Nerve Stimulation with Magnetic Pulses
Widely dispersed field,
minimal recruitment
Weak local field, minimal recruitment
Strong local field,
maximal recruitment
SCS
Widely dispersed field,
minimal recruitment
DRG
Conventional PNS
Weak local field, minimal recruitment
mPNS
Strong local field,
maximal recruitment
THE TREATMENT PROTOCOL
Empowering You to Alleviate Pain In As Little As 13.5 Minutes
Axon Therapy mPNS demonstrates significantly higher peak pain reduction for responding patients (71% reduction at 90 days) compared to leading PNS competitors (57% reduction at 60 days).
Month 1
Week 1: 3 Treatments
1 treatment per day for 3 consecutive days
Week 2-4: Weekly
1 treatment per week
Month 2
Month 2: Bi-Weekly
2 treatments every 2 weeks (bi-monthly)
Month 3
Month 3 +: Monthly
1 treatment per month
CLINICAL EVALUATION DATA
Initial Field Trials & Key Insights
In a 7-week pilot evaluation conducted at Neuralace Medical’s Federal Reference Account–the Augusta VAMC–Axon Therapy mPNS demonstrated a significant response rate and reduced avg. pain scored in patients experiencing chronic neuropathic pain.
⅔ of Patients Saw ≥50% Reduction in Pain1
16 of 24 Patients Responded
Average % Pain Relief
No Data Found
16 of 24 Patients Responded
Average % Pain Relief
No Data Found
